Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy
- 1 January 2011
- journal article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 56-61
- https://doi.org/10.3816/clc.2011.n.008
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599Journal of Clinical Oncology, 2008
- EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase ActivityCancer Research, 2007
- Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patientsLung Cancer, 2006
- Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clampBritish Journal of Cancer, 2006
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Lung cancer in the elderlyEuropean Journal of Cancer, 1997